Irreversible inhibition of EGFR: Modeling the combined pharmacokinetic-pharmacodynamic relationship of osimertinib and its active metabolite AZ5104

Molecular Cancer Therapeutics

Volumn 15, Issue 10, 2016, Pages 2378-2387

  Yates, James W T ^a   Ashton, Susan ^a   Cross, Darren ^a   Mellor, Martine J ^a   Powell, Steve J ^a   Ballard, Peter ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZ 5104; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; OSIMERTINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CANCER INHIBITION; CONTROLLED STUDY; COVALENT BOND; DRUG CLEARANCE; DRUG EFFICACY; DRUG POTENTIATION; FRACTION ABSORBED; IN VIVO STUDY; MOUSE; NONHUMAN; PREDICTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; ALGORITHM; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; CHEMISTRY; DISEASE MODEL; DRUG SCREENING; HUMAN; TUMOR CELL LINE;

ALGORITHMS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; HUMANS; MICE; MODELS, BIOLOGICAL; PIPERAZINES; PROTEIN KINASE INHIBITORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990985638     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-16-0142     Document Type: Article

References (10)

1. Milligan PA, Brown MJ, Marchant B, Martin SW, van der Graaf PH, Benson N, et al. Model-based drug development: a rational approach to efficiently accelerate drug development. Clin Pharmacol Ther 2013;9:502-14.
2. Visser SAG, Aurell M, Jones RDO, Schuck VJA, Egnell A-C, Peters S, et al. Model-based drug discovery: implementation and impact. Drug Discov Today 2013;18:764-75.
3. Bueters T, Ploeger BA, Visser SAG. The virtue of translational PKPD modelling in drug discovery: selecting the right clinical candidate while sparing animal lives. Drug Discov Today 2013;18:853-62.
4. Finlay MRV, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, et al. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem 2014;57:8249-67.
5. Cross DAE, Ashton SE, Ghiorghiu S, Eberlein C, Nebhan CA, Spitzler PJ, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014;4:1046-61.
6. Cheung SYA, Yates JWT, Aarons L. The design and analysis of parallel experiments to produce structurally identifiable models. J Pharmacokinet Pharmacodyn 2013;40:93-100.
7. Schwartz PA, Kuzmic P, Solowiej J, Bergqvist S, Bolanos B, Almaden C, et al. Covalent EGFR inhibitor analysis reveals importance of reversible interactions to potency and mechanism of drug resistance. Proc Natl Acad Sci U S A 2014;111:173-8.
8. Kirouac DC, Du JY, Lahdenranta J, Overland R, Yarar D, Paragas V, et al. Computational modeling of ERBB2-amplified breast cancer identifies combined ErbB2/3 blockade as superior to combination of MEK and AKT inhibitors. Sci Signal 2013;6:ra68.
9. Evans ND, Dimelow RJ, Yates JWT. Modelling of tumor growth and cytotoxic effect of docetaxel in xenografts. Comput Methods Programs Biomed 2014;114:e3-e13.
10. Jänne PS, Yang JC-H, Kim D-W, Planchard D, Ohe Y, Ramalingham SS, et al. AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer. N Engl J Med 2015;372:1689-99.